Literature DB >> 1390306

Effective prevention of chemotherapy--induced phlebitis by low-dose heparin: a prospective randomised trial.

B Thürlimann1, I Bachmann.   

Abstract

In a prospective randomised trial patients receiving multiple-day chemotherapy and heparin had significantly fewer local complications at the site of venous access than patients who had chemotherapy alone. The need to move peripheral venous catheters to other sites was decreased significantly, from 36% to 6%. Prophylaxis of phlebitis with low-dose continuous heparin is safe, simple, cheap and effective. It facilitates administration of multiple-day chemotherapy for the patients, the nurses and the physicians.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1390306     DOI: 10.1093/oxfordjournals.annonc.a058188

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  4 in total

Review 1.  Heparin versus 0.9% sodium chloride locking for prevention of occlusion in central venous catheters in adults.

Authors:  Eduardo López-Briz; Vicente Ruiz Garcia; Juan B Cabello; Sylvia Bort-Martí; Rafael Carbonell Sanchis
Journal:  Cochrane Database Syst Rev       Date:  2022-07-18

2.  Venous damage prevention by defibrotide in vinorelbine-treated patients.

Authors:  M Mare; R Maisano; N Caristi; V Adamo; G Altavilla; R Carboni; S Munaò; F La Torre
Journal:  Support Care Cancer       Date:  2003-05-16       Impact factor: 3.603

Review 3.  Anticoagulation for people with cancer and central venous catheters.

Authors:  Lara A Kahale; Ibrahim G Tsolakian; Maram B Hakoum; Charbel F Matar; Maddalena Barba; Victor Ed Yosuico; Irene Terrenato; Francesca Sperati; Holger Schünemann; Elie A Akl
Journal:  Cochrane Database Syst Rev       Date:  2018-06-01

Review 4.  Heparin versus 0.9% sodium chloride locking for prevention of occlusion in central venous catheters in adults.

Authors:  Eduardo López-Briz; Vicente Ruiz Garcia; Juan B Cabello; Sylvia Bort-Martí; Rafael Carbonell Sanchis; Amanda Burls
Journal:  Cochrane Database Syst Rev       Date:  2018-07-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.